Phospholamban Antikörper (AA 1-52)
-
- Target Alle Phospholamban (PLN) Antikörper anzeigen
- Phospholamban (PLN)
-
Bindungsspezifität
- AA 1-52
-
Reaktivität
- Human
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser Phospholamban Antikörper ist unkonjugiert
-
Applikation
- ELISA, Immunohistochemistry (IHC)
- Kreuzreaktivität
- Human
- Aufreinigung
- >95%, Protein G purified
- Immunogen
- Recombinant Human Cardiac phospholamban protein (1-52AA)
- Isotyp
- IgG
- Top Product
- Discover our top product PLN Primärantikörper
-
-
- Applikationshinweise
- Recommended dilution: IHC:1:20-1:200,
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Liquid
- Buffer
-
Preservative: 0.03 % Proclin 300
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4 - Konservierungsmittel
- ProClin
- Vorsichtsmaßnahmen
- This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
- Lagerung
- -20 °C,-80 °C
- Informationen zur Lagerung
- Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
-
- Target
- Phospholamban (PLN)
- Andere Bezeichnung
- PLN (PLN Produkte)
- Synonyme
- LOC100226261 antikoerper, plb antikoerper, cmd1p antikoerper, CMD1P antikoerper, CMH18 antikoerper, PLB antikoerper, Plb antikoerper, Plm antikoerper, phospholamban antikoerper, PLN antikoerper, pln antikoerper, Pln antikoerper
- Hintergrund
-
Background: Reversibly inhibits the activity of ATP2A2 in cardiac sarcoplasmic reticulum by decreasing the apparent affinity of the ATPase for Ca(2+). Modulates the contractility of the heart muscle in response to physiological stimuli via its effects on ATP2A2. Modulates calcium re-uptake during muscle relaxation and plays an important role in calcium homeostasis in the heart muscle. The degree of ATP2A2 inhibition depends on the oligomeric state of PLN. ATP2A2 inhibition is alleviated by PLN phosphorylation.
Aliases: Cardiac phospholamban antibody, CMD1P antibody, CMH18 antibody, PLB antibody, Pln antibody, PPLA_HUMAN antibody
- UniProt
- P26678
- Pathways
- Negative Regulation of Transporter Activity
-